Humanwell Healthcare (SHA:600079), through subsidiary RFSW Holding, agreed to sell its 16.34% equity in Lefusi Health Industry to Wuhan Hairun Biotechnology for 1.06 billion yuan, according to a Shanghai bourse filing on Wednesday.
After the transaction, the pharmaceutical company will no longer hold any equity in Lefusi.
The company's shares rose 2% during the midday trade.